BioCryst licenses navenibart to Neopharmed Gentili in Europe for $70M upfront plus milestones

BIOCRYST PHARMACEUTICALS INC

BioCryst receives $70M upfront and up to $275M in regulatory/sales milestones from Neopharmed Gentili affiliate.
Tiered royalties on net sales of navenibart in Europe range from 18% to 30%.
Navenibart Phase 3 in hereditary angioedema on track for US regulatory filing by end of 2027.
Agreement builds on prior 2025 deal for sale of European ORLADEYO business to Neopharmed Gentili.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.